48,466
edits
Difference between revisions of "B72.3"
Jump to navigation
Jump to search
no edit summary
| (One intermediate revision by the same user not shown) | |||
| Line 11: | Line 11: | ||
| Subspecial = | | Subspecial = | ||
| Pattern = cytoplasmic | | Pattern = cytoplasmic | ||
| Positive = [[malignant mesothelioma]] | | Positive = most carcinomas | ||
| Negative = [[malignant mesothelioma]] | |||
| Other = | | Other = | ||
}} | }} | ||
| Line 18: | Line 18: | ||
==Use== | ==Use== | ||
===Negative=== | |||
*[[Mesothelioma]] - stains ~3% (6 of 196<ref name=pmid29048219/>). | |||
===Positive=== | ===Positive=== | ||
* | *Most carcinomas.<ref name=pmid1866206>{{Cite journal | last1 = Betta | first1 = PG. | last2 = Pavesi | first2 = M. | last3 = Pastormerlo | first3 = M. | last4 = Tallarida | first4 = F. | last5 = Bellingeri | first5 = D. | last6 = Bocca | first6 = R. | title = Use of monoclonal antibody B72.3 as a marker of metastatic carcinoma cells in neoplastic effusions. | journal = Pathologica | volume = 83 | issue = 1083 | pages = 99-104 | month = | year = | doi = | PMID = 1866206 }}</ref> | ||
=== | |||
==See also== | ==See also== | ||